[Featured Stock] Oscotec Develops New Antibody for Alzheimer’s... “Confirmed Potential for Dementia Treatment”↑

Oscotec is showing strong performance. The news that Adel has developed a new antibody that may help inhibit the progression of tau pathology in degenerative brain diseases such as Alzheimer's disease is believed to have fueled expectations for the start of a joint clinical trial in the United States this year.

As of 10:35 AM on the 16th, Oscotec is trading at 18,960 KRW, up 3.6% from the previous day.

According to industry sources, researchers from Adel and Seoul Asan Medical Center have developed a monoclonal antibody that may help inhibit pathological progression in various tauopathies including Alzheimer's disease.

This antibody specifically targets tau-acK280, an acetylated tau protein at lysine 280, which is considered to play a key role in the development and spread of tauopathies. Tauopathies are a group of diseases characterized by the accumulation of tau protein in the brain, which can lead to neuronal death and cognitive decline. Alzheimer's disease is the most common type of tauopathy.

This research was conducted with support from the Ministry of Science and ICT's Mid-career Research Program and the Ministry of Health and Welfare's Nonclinical Development Program, and was published online in the international journal The Journal of Clinical Investigation.

Adel and Oscotec plan to initiate a Phase 1 clinical trial in the United States this year. The two companies signed a joint development agreement for ADEL-Y01 in 2020.

This content was produced with the assistance of AI translation services.